Revenue grew with portfolio transformation
Sales grew 21% year on year
Watch: Check recurring demand
Home / Research / GlaxoSmithKline Pharmaceuticals Limited
Revenue grew with portfolio transformation
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdedeaad-c705-4732-978f-46ff1ae54877.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdedeaad-c705-4732-978f-46ff1ae54877.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdedeaad-c705-4732-978f-46ff1ae54877.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdedeaad-c705-4732-978f-46ff1ae54877.pdf
Sales grew 21% year on year
Watch: Check recurring demand
Margin nevertheless slipped
Watch: Track gross margin
Tax-refund interest contributed
Watch: Separate recurring profit
H1 margin was 33%, different period
Watch: Track mix and costs
GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO) | Q2 FY27, quarter ended 30 September 2026 | Standalone India pharmaceuticals | WATCH
The central investment question: GSK India delivered strong sales growth, but its reported profit improvement needs careful interpretation. Revenue rose 21% to ₹1,180 crore and EBITDA rose 20% to ₹400 crore, while profit after tax before exceptional items rose 33% to ₹335 crore. The presentation attributes part of the profit-margin improvement to interest on an income-tax refund, which is not the same as recurring medicine sales. The next quarter must show whether the newer oncology, respiratory and adult-vaccine portfolio can sustain growth without depending on this benefit. [S1][S2]
| Standalone metric | Q2 FY27 | H1 FY27 | Interpretation |
|---|---|---|---|
| Revenue | ₹1,180 crore | ₹2,104 crore | Q2 +21%, H1 +18% year on year |
| EBITDA | ₹400 crore | ₹693 crore | Q2 +20%, H1 +18% year on year |
| EBITDA margin | 34% | 33% | Q2 down 50 basis points year on year |
| PAT before exceptional items | ₹335 crore | ₹588 crore | Q2 +33%, H1 +29% year on year |
| PAT margin | 29% | 28% | Q2 up 260 basis points year on year |
| Q2 earnings per share | ₹19.76 | — | Q2 +32% year on year |
What changed: Innovation products contributed 7% of sales, compared with 3% in the prior-year quarter. This includes the company's defined oncology, new respiratory and adult-vaccine portfolio. At the same time, currency depreciation and input costs diluted gross margins, only partly offset by price increases. Strong sales growth therefore did not produce an expanding EBITDA margin in Q2. [S2]
Investor takeaways
GSK India is a pharmaceutical business with established prescription medicines, vaccines and newer specialty products. The company is shifting more attention toward oncology, respiratory treatments and adult immunisation while continuing to defend its existing brands. The investment case depends on whether these newer products can become a larger, profitable share of sales while the established portfolio remains competitive. [S1][S2]
The latest quarter shows momentum but not a simple margin expansion. Sales grew 21%, EBITDA grew 20%, and the EBITDA margin edged down by 50 basis points. That means sales volume, pricing and product mix are moving in the right direction overall, but cost pressure is still visible. Investors should distinguish a stronger product portfolio from a one-quarter improvement in profit after tax supported by interest income. [S2]
A stronger valuation case would require sustained prescription demand, improving mix from innovative medicines and vaccines, stable gross margins, and recurring profit growth excluding unusual interest receipts. The filings used here do not establish a current share price, forward valuation multiple or independently reconstructed cash-flow forecast. Rather than infer a target price, the investment stance is WATCH while the portfolio shift matures.
Decision priorities
The presentation reports standalone Q2 FY27 revenue of ₹1,180 crore, EBITDA of ₹400 crore and profit after tax before exceptional items of ₹335 crore. Year-on-year growth was 21%, 20% and 33%, respectively. EBITDA margin was 34%, down 50 basis points, while PAT margin was 29%, up 260 basis points. The difference is important: profitability improved more at the PAT level than at the operating level. [S2]
Management explained that currency depreciation and higher input costs weighed on gross margin, with pricing partly offsetting these effects. The company also received interest on an income-tax refund, which helped the PAT margin. That interest should not be extrapolated as if it were recurring profit from medicines. Investors can recognise the reported earnings while still asking what the core business earned without the unusual interest benefit. [S1][S2]
The first half offers a useful cross-check. H1 revenue reached ₹2,104 crore, up 18%; EBITDA was ₹693 crore, up 18%; and PAT before exceptional items was ₹588 crore, up 29%. H1 EBITDA margin was 33%, up 10 basis points year on year, while PAT margin reached 28%, up 230 basis points. These H1 figures cover six months and must not be compared directly with three-month Q2 amounts as if the periods were identical. [S2]
The company's PAT figures in the cited financial highlights are explicitly before exceptional items. This is a presentation-defined measure and should not be silently relabelled statutory net profit. The report preserves that distinction rather than inventing a reconciliation to another earnings basis.
| Earnings measure | Q2 FY27 | H1 FY27 | Reported year-on-year change |
|---|---|---|---|
| Revenue | ₹1,180 crore | ₹2,104 crore | +21% / +18% |
| EBITDA | ₹400 crore | ₹693 crore | +20% / +18% |
| PAT before exceptional items | ₹335 crore | ₹588 crore | +33% / +29% |
| EBITDA margin | 34% | 33% | -50 / +10 basis points |
| PAT margin | 29% | 28% | +260 / +230 basis points |
Earnings-quality checks
GSK India's established medicines remain the commercial base, while oncology, newer respiratory products and adult vaccines are the growth platforms. The presentation defines its innovation portfolio as oncology products including Jemperli and Zejulo, newer respiratory products Nucala and Trelegy, and adult vaccine Shingrix. Their combined share of sales increased from 3% in the prior-year quarter to 7% in Q2 FY27. That is a notable change in product mix, though the disclosure does not separately quantify every brand's revenue. [S2]
In general medicines, the company reported improving market-share indicators. The presentation shows unit market share moving from 31.7% to 33.2% in its stated comparison, while value market share moved from 26.3% to 26.7%. These are market-data measures with their own scope, not a direct calculation of GSK's total revenue growth. The distinction matters because market value can rise through prices even when unit demand changes more slowly. [S2]
The established vaccine business reported a 21.5% value market share. Specific brand indicators include Fluarix unit market share of 22.5%, Havrix at 33.8% and Boostrix at 32.9%, as presented for Q2 FY27. These brands address different vaccine categories and should not be added together to produce a company-wide market share. [S2]
The presentation also reported more than 4,000 patients benefiting from its newer severe-asthma programme. That is a useful access indicator, but it is not equivalent to paying patients, sales, revenue recognition or recurring profit. For specialty medicines, the economic question is how many patients remain on treatment, what reimbursement and access arrangements apply, and how launch spending compares with sales. [S2]
Portfolio questions
Management described the quarter as one of strong execution and continued portfolio transformation. The 21% revenue growth reflected established-brand performance alongside the newer products, with a favourable prior-year base also contributing. This makes the next comparable quarter important: growth should be judged against a stronger base, not simply annualised from Q2. [S1][S2]
The company's strategy has three broad priorities: deliver growth from the established and innovative portfolios, simplify operations through technology, and accelerate research and development. These are strategic directions rather than booked financial results. Investors should ask which new products are actually launched, how quickly they gain patient access and whether launch costs are reflected in operating margins. [S2]
Management's financial commentary points to a practical challenge. Price increases only partly offset currency and input-cost pressure, leaving EBITDA margin slightly below the prior-year level. At the same time, interest on a tax refund helped the bottom line. This combination makes it important to question whether the underlying gross-margin pressure is temporary and how the company expects to improve profitability without relying on other income. [S1][S2]
The analyst discussion and presentation do not establish a reliable brand-by-brand revenue forecast or guaranteed launch uptake. A better monitoring approach is to compare quarterly innovation sales mix, established-brand unit share and EBITDA margin with subsequent disclosures. That connects management's portfolio strategy to measurable results.
GSK India's Q2 financial highlights establish operating earnings of ₹400 crore and PAT before exceptional items of ₹335 crore. However, these amounts are not cash flow. EBITDA excludes financing, taxes, depreciation and working-capital movements, while profit after tax includes accounting items and the tax-refund interest benefit identified by management. Investors should not treat either figure as cash available for dividends or investment. [S2]
The innovation strategy involves launches, medical engagement, distribution and market access. Some of these costs occur before products reach scale. Established medicines and vaccines may help fund that investment, but the available cited financial highlights do not provide a complete, comparable quarterly cash-flow, capex and net-debt schedule. Accordingly, this report does not assign an unsupported free-cash-flow conversion rate or payback period.
The balance-sheet questions are still specific. Did trade receivables and inventory rise faster than sales? Did cash taxes change after the refund? How much operating cash is available after launch expenditure and maintenance investment? A credible next-quarter update should reconcile reported profit with cash generated from operations and distinguish recurring cash earnings from one-time receipts.
Capital and cash checks
Bull case: Innovation sales continue to take a larger share of revenue beyond Q2's 7%, while established brands protect market share. The company offsets currency and input-cost inflation through pricing, mix and efficiency. EBITDA margin stabilises or improves, and recurring profit grows without relying on unusual interest income. Evidence would include sustained prescription uptake, stronger gross margin and cash conversion. [S2]
Base case: Sales remain healthy but growth moderates as the comparison base becomes more demanding. Newer oncology, respiratory and vaccine products expand gradually, while launch spending and input costs keep operating margins broadly stable. Reported PAT growth becomes less dramatic when tax-refund interest does not recur. This would still be a viable portfolio transition, but one requiring patience and careful valuation.
Bear case: Currency and input costs outpace price increases, established brands lose share, or specialty launches take longer to achieve patient access. The innovation portfolio's sales share stalls, EBITDA margin falls and reported profit growth slows once unusual other income fades. A premium valuation would be harder to sustain without visible operating improvement.
What would disprove the optimistic case
Stance: WATCH. GSK India's Q2 FY27 performance was strong on revenue and encouraging on innovation mix, but the profit story is less straightforward. EBITDA margin slipped slightly and tax-refund interest helped PAT. The most important next-quarter question is whether the product transition is producing durable operating earnings rather than a temporary lift to reported profit. [S1][S2]
| Next-quarter item | Q2 FY27 reference | Why it matters |
|---|---|---|
| Standalone revenue | ₹1,180 crore | Tests continued product demand |
| Revenue growth | 21% YoY | Compare against a stronger base |
| EBITDA | ₹400 crore | Measures operating earnings |
| EBITDA margin | 34% | Tests currency and input-cost pressure |
| PAT before exceptional items | ₹335 crore | Separate recurring from tax-related income |
| PAT margin | 29% | Check sustainability of bottom-line improvement |
| Innovation share of sales | 7% | Tracks oncology, respiratory and adult vaccines |
| General medicines unit market share | 33.2% in disclosed comparison | Tests established-brand demand |
| Established vaccine value share | 21.5% | Measures competitive position |
| Q2 EPS | ₹19.76 | Check reported share-basis consistency |
The next results should answer four questions clearly. First, how much revenue growth comes from established brands versus newer products? Second, is gross margin recovering as pricing offsets imported input costs? Third, how much PAT growth remains without the tax-refund interest? Fourth, are patient access and vaccine volumes improving enough to support future sales? [S1][S2]
Reporting limitations relevant to decisions: All financial figures here are standalone. PAT is presented before exceptional items, and the tax-refund interest helped its margin. H1 numbers cover six months, while Q2 covers three. Market-share figures refer to specified therapy and vaccine markets and should not be treated as total company market share. The cited material does not provide a full comparable cash-flow and capex bridge.
All monetary figures are Indian rupees crore unless otherwise indicated. Percentage changes and margin comparisons are those disclosed by the company for the stated standalone period.
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdedeaad-c705-4732-978f-46ff1ae54877.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdedeaad-c705-4732-978f-46ff1ae54877.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdedeaad-c705-4732-978f-46ff1ae54877.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdedeaad-c705-4732-978f-46ff1ae54877.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.